Clinical Neurology and Neurosurgery
Volume 112, Issue 7 , Pages 621-624 , September 2010

Genomics in multiple sclerosis

  • Mario Habek

      Affiliations

    • Department of Neurology, School of Medicine, University of Zagreb and University Hospital Center Zagreb, Zagreb, Croatia
    • Refferal Center for Demyelinating Diseases of the Central Nervous System, School of Medicine, University of Zagreb and University Hospital Center Zagreb, Zagreb, Croatia
    • Corresponding Author InformationCorresponding author at: University Department of Neurology, Zagreb School of Medicine and University Hospital Center, Kišpatićeva 12, HR-10000 Zagreb, Croatia. Tel.: +385 98883323; fax: +385 12421891.
    • ,
  • Fran Borovečki

      Affiliations

    • Department of Neurology, School of Medicine, University of Zagreb and University Hospital Center Zagreb, Zagreb, Croatia
    • Department for Functional Genomics, Center for Translational and Clinical Research, Zagreb, Croatia
    • ,
  • Vesna V. Brinar

      Affiliations

    • Department of Neurology, School of Medicine, University of Zagreb and University Hospital Center Zagreb, Zagreb, Croatia
    • Refferal Center for Demyelinating Diseases of the Central Nervous System, School of Medicine, University of Zagreb and University Hospital Center Zagreb, Zagreb, Croatia

Received 1 March 2010 ,Revised 23 March 2010 ,Accepted 29 March 2010.

References 

  1. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430–1438
  2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95
  3. Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol. 2004;61:1613–1615
  4. Lutterotti A, Berger T, Reindl M. Biological markers for multiple sclerosis. Curr Med Chem. 2007;14:1956–1965
  5. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain. 2004;127:1463–1478
  6. Comabella M, Martin R. Genomics in multiple sclerosis—current state and future directions. J Neuroimmunol. 2007;187:1–8
  7. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM. Expression profiling using cDNA microarrays. Nat Genet. 1999;21:10–14
  8. Barrett JC, Kawasaki ES. Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression. Drug Discov Today. 2003;8:134–141
  9. Whitney LW, Ludwin SK, McFarland HF, Biddison WE. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Neuroimmunol. 2001;121:40–48
  10. Consortium MAQC. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006;24:1151–1161
  11. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29:365–371
  12. Whitney LW, Becker KG, Tresser NJ, Caballero-Ramos CI, Munson PJ, Prabhu VV, et al. Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. Ann Neurol. 1999;46:425–428
  13. Bomprezzi R, Ringnér M, Kim S, Bittner ML, Khan J, Chen Y, et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet. 2003;12:2191–2199
  14. Mandel M, Gurevich M, Pauzner R, Kaminski N, Achiron A. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol. 2004;138:164–170
  15. Tajouri L, Mellick AS, Ashton KJ, Tannenberg AE, Nagra RM, Tourtellotte WW, et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res. 2003;119:170–183
  16. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis. Clin Neurol Neurosurg. 2004;106:223–229
  17. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain. 2003;126:1048–1057
  18. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8:500–508
  19. Lindberg RL, De Groot CJ, Certa U, Ravid R, Hoffmann F, Kappos L, et al. Multiple sclerosis as a generalized CNS disease—comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. J Neuroimmunol. 2004;152:154–167
  20. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 2003;13:554–573
  21. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59:478–489
  22. Cunnea P, McMahon J, O’Connell E, Mashayekhi K, Fitzgerald U, McQuaid S. Gene expression analysis of the microvascular compartment in multiple sclerosis using laser microdissected blood vessels. Acta Neuropathol. 2009;[Epub ahead of print]
  23. Kinter J, Zeis T, Schaeren-Wiemers N. RNA profiling of MS brain tissues. Int MS J. 2008;15:51–58
  24. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA, et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA. 2003;100:1896–1901
  25. Radich JP, Mao M, Stepaniants S, Biery M, Castle J, Ward T, et al. Individual-specific variation of gene expression in peripheral blood leukocytes. Genomics. 2004;83:980–988
  26. Goertsches R, Zettl UK. MS therapy research applying genome-wide RNA profiling of peripheral blood. Int MS J. 2007;14:98–107
  27. Ramanathan M, Weinstock-Guttman B, Nguyen LT, Badgett D, Miller C, Patrick K, et al. In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J Neuroimmunol. 2001;116:213–219
  28. Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol. 2004;55:410–417
  29. Wandinger KP, Stürzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol. 2001;50:349–357
  30. Koike F, Satoh J, Miyake S, Yamamoto T, Kawai M, Kikuchi S, et al. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J Neuroimmunol. 2003;139:109–118
  31. Stürzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain. 2003;126:1419–1429
  32. Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, Hall D, et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol. 2003;171:2694–2702
  33. Serrano-Fernández P, Möller S, Goertsches R, Fiedler H, Koczan D, Thiesen HJ, et al. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity. 2009;[Epub ahead of print]
  34. Goertsches RH, Hecker M, Koczan D, Serrano-Fernandez P, Moeller S, Thiesen HJ, et al. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics. 2010;11:147–161
  35. Achiron A, Feldman A, Gurevich M. Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. Dis Markers. 2009;27:63–73
  36. Wandinger KP, Sturzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol. 2001;50:349–357

PII: S0303-8467(10)00101-0

doi: 10.1016/j.clineuro.2010.03.028

Clinical Neurology and Neurosurgery
Volume 112, Issue 7 , Pages 621-624 , September 2010

Article Tools